Skip to main content
Clinical Trials/NCT05050825
NCT05050825
Unknown
N/A

Validation of an Assisted Medical Care Strategy Composed of a Clinical Decision Support System and RDTs to Reduce Antibiotic Prescription in Non-severe Acute Disease in Children 15 Years Old and Younger in Senegal

Foundation for Innovative New Diagnostics, Switzerland4 sites in 1 country470 target enrollmentMay 3, 2021

Overview

Phase
N/A
Intervention
Not specified
Conditions
Malaria
Sponsor
Foundation for Innovative New Diagnostics, Switzerland
Enrollment
470
Locations
4
Primary Endpoint
Non-inferiority of the CDSA strategy when compared to routine practice in terms of clinical status assessed at Day 7
Last Updated
4 years ago

Overview

Brief Summary

This trial aims to validate a novel clinical care strategy based on a electronic clinical decision support algorithm (CDSA) combined with point of care rapid diagnostic tests by evaluating its impact on antibiotic prescription and clinical outcome of children and adolescent presenting at primary healthcare facilities with non-severe acute illness compared to routine practice. The trial also aims to assess the usability of the CDSA strategy. The study will be conducted in primary healthcare facilities across different epidemiological regions of Senegal.

Registry
clinicaltrials.gov
Start Date
May 3, 2021
End Date
December 15, 2021
Last Updated
4 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Foundation for Innovative New Diagnostics, Switzerland
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Ongoing fever or diarrhea
  • ongoing fever will be defined objectively or as a reported fever, defined as : axillary temperature ≥37.5°C or tympanic, oral or rectal temperature ≥38.0°C; and fever duration ≤ 10 days
  • ongoing diarrhea will be defined as at least 3 abnormal stools during the last 24hrs
  • First consultation for the current illness
  • Feasibility of contact between the patient (or his/her designated relative) and the study team at day 3 and day 7
  • Written informed consent by the caretaker/legally acceptable representative

Exclusion Criteria

  • Infants less than 6 months of age
  • Age ≥ 15 years
  • Clinical status requiring immediate transfer to an appropriate care facility/ severe illness

Outcomes

Primary Outcomes

Non-inferiority of the CDSA strategy when compared to routine practice in terms of clinical status assessed at Day 7

Time Frame: 4 months

This will be measured as point estimates of the percent change of patient with resolved illness at Day 7 in the intervention arm, as compared to the control arm.

Superiority of the CDSA strategy when compared to routine practice in terms of antibiotic prescription at Day 0

Time Frame: 4 months

This will be measured as point estimates of the percent change of antibiotic prescription at Day 0 in the intervention arm, as compared to the control arm and to site-specific historical data. This measure aims to assess rational use of antibiotics using the CDSA strategy compared to routine practice.

Secondary Outcomes

  • Diagnostic performance of the dengue rapid diagnostic test (RDT)(4 months)
  • Antibiotic prescription rate during 7 days of follow-up in the intervention arm compared to the control arm(4 months)
  • Identification of risk factors associated with viral and bacterial infections(4 months)

Study Sites (4)

Loading locations...

Similar Trials